CL2013000595A1 - Metodo de diagnostico in vitro para determinar si un paciente con cancer es susceptible al tratamiento con un inhibidor de la proteina tirosina quinasa 2 (ptk2); kit farmaceutico que comprende un inhibidor de ptk2; uso de un anticuerpo de e-cadherina para diagnostico en vivo. - Google Patents
Metodo de diagnostico in vitro para determinar si un paciente con cancer es susceptible al tratamiento con un inhibidor de la proteina tirosina quinasa 2 (ptk2); kit farmaceutico que comprende un inhibidor de ptk2; uso de un anticuerpo de e-cadherina para diagnostico en vivo.Info
- Publication number
- CL2013000595A1 CL2013000595A1 CL2013000595A CL2013000595A CL2013000595A1 CL 2013000595 A1 CL2013000595 A1 CL 2013000595A1 CL 2013000595 A CL2013000595 A CL 2013000595A CL 2013000595 A CL2013000595 A CL 2013000595A CL 2013000595 A1 CL2013000595 A1 CL 2013000595A1
- Authority
- CL
- Chile
- Prior art keywords
- ptk2
- inhibitor
- susceptible
- treatment
- tyrosine kinase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10180981 | 2010-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013000595A1 true CL2013000595A1 (es) | 2014-05-09 |
Family
ID=43085773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013000595A CL2013000595A1 (es) | 2010-09-28 | 2013-03-01 | Metodo de diagnostico in vitro para determinar si un paciente con cancer es susceptible al tratamiento con un inhibidor de la proteina tirosina quinasa 2 (ptk2); kit farmaceutico que comprende un inhibidor de ptk2; uso de un anticuerpo de e-cadherina para diagnostico en vivo. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20120244141A1 (es) |
| EP (1) | EP2622352B1 (es) |
| JP (1) | JP2013540108A (es) |
| KR (1) | KR20130097196A (es) |
| CN (1) | CN103124905A (es) |
| AU (1) | AU2011310692A1 (es) |
| BR (1) | BR112013007405A2 (es) |
| CA (1) | CA2807250A1 (es) |
| CL (1) | CL2013000595A1 (es) |
| EA (1) | EA201300410A1 (es) |
| MX (1) | MX2013002820A (es) |
| PH (1) | PH12013500560A1 (es) |
| WO (1) | WO2012041796A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012110773A1 (en) | 2011-02-17 | 2012-08-23 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| DK2675794T3 (da) | 2011-02-17 | 2019-05-06 | Cancer Therapeutics Crc Pty Ltd | Selektive fak-inhibitorer |
| CN116183527B (zh) * | 2022-12-19 | 2025-07-29 | 南昌研湾生物科技有限公司 | 非诊断目的的用于预测肿瘤患者放射敏感性的体外快速检测方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| ATE374248T1 (de) | 1996-06-27 | 2007-10-15 | Vlaams Interuniv Inst Biotech | Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren |
| KR20030094281A (ko) * | 2001-03-12 | 2003-12-11 | 모노젠, 인크. | 세포에 기초한 질병상태의 검출 및 질병상태의 구별 |
| EP1545529A4 (en) | 2002-09-30 | 2010-03-03 | Bristol Myers Squibb Co | NEW TYROSINE KINASE HEMMER |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| EP1558645B1 (en) | 2002-11-08 | 2011-07-27 | Ablynx N.V. | Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| SI1625121T1 (sl) | 2002-12-20 | 2010-04-30 | Pfizer Prod Inc | Derivati pirimidina za zdravljenje abnormalne rasti celic |
| US20050241961A1 (en) | 2004-04-29 | 2005-11-03 | Ferguson Patrick J | Synthetic suture card |
| MXPA06013164A (es) | 2004-05-14 | 2007-02-13 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal. |
| EP1758887A1 (en) | 2004-05-14 | 2007-03-07 | Pfizer Products Incorporated | Pyrimidine derivatives for the treatment of abnormal cell growth |
| EA200601796A1 (ru) | 2004-05-14 | 2007-04-27 | Пфайзер Продактс, Инк. | Пиримидиновые производные для лечения аномального клеточного роста |
| GB0419160D0 (en) | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| FR2881742B1 (fr) | 2005-02-10 | 2007-09-07 | Aventis Pharma Sa | Pyrroles substitues, compositions les contenant, procede de fabrication et utilisation |
| CA2632149C (en) | 2005-12-01 | 2011-11-15 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| EP1966207A2 (en) | 2005-12-21 | 2008-09-10 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| CA2681038A1 (en) * | 2007-03-16 | 2008-09-25 | University Of Florida Research Foundation | Kinase protein binding inhibitors |
| EP2134689B1 (en) | 2007-03-16 | 2014-04-23 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
| DK2146779T3 (en) | 2007-04-18 | 2016-11-28 | Pfizer Prod Inc | Sulfonylamid derivatives to treat abnormal cell growth. |
| DE102007031988A1 (de) | 2007-07-10 | 2009-01-15 | Continental Aktiengesellschaft | Zuführungseinrichtung für streifenförmige Bauteile |
| FR2919061B1 (fr) * | 2007-07-19 | 2009-10-02 | Biomerieux Sa | Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal. |
| CN101353695B (zh) * | 2007-07-23 | 2013-05-01 | 上海市肿瘤研究所 | 尿沉淀dna甲基化谱式分析诊断膀胱癌的方法和试剂盒 |
| EP2065380A1 (en) | 2007-08-22 | 2009-06-03 | F.Hoffmann-La Roche Ag | Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer |
| US8048621B2 (en) * | 2007-10-03 | 2011-11-01 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| EP2047849A1 (en) | 2007-10-08 | 2009-04-15 | KTB Tumorforschungsgesellschaft mbH | Use of indolocarbazole imides as protein kinase inhibitors for the treatment of hematologic and solid tumors |
| US8461147B2 (en) | 2007-12-03 | 2013-06-11 | Boehringer Ingelheim International Gmbh | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
| WO2009105498A1 (en) * | 2008-02-19 | 2009-08-27 | Smithkline Beecham Corporation | Anilinopyridines as inhibitors of fak |
| CN102124000B (zh) | 2008-06-17 | 2014-09-17 | 阿斯利康(瑞典)有限公司 | 吡啶化合物 |
| JO3067B1 (ar) | 2008-10-27 | 2017-03-15 | Glaxosmithkline Llc | بيرميدينات بيرازولو امينو كمثبطات ل fak |
| UY32240A (es) | 2008-11-14 | 2010-06-30 | Boeringer Ingelheim Kg | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. |
| AR074210A1 (es) | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina como inhibidores de ptk2-quinasa |
| TW201024281A (en) | 2008-11-24 | 2010-07-01 | Boehringer Ingelheim Int | New compounds |
| US20110071158A1 (en) | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
| US8410126B2 (en) | 2009-05-29 | 2013-04-02 | Boehringer Ingelheim International Gmbh | Pyrimidine inhibitors of PKTK2 |
| US8466155B2 (en) | 2009-10-02 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Pyrimidines |
-
2011
- 2011-09-20 US US13/237,833 patent/US20120244141A1/en not_active Abandoned
- 2011-09-26 EP EP11761079.0A patent/EP2622352B1/en active Active
- 2011-09-26 AU AU2011310692A patent/AU2011310692A1/en not_active Abandoned
- 2011-09-26 EA EA201300410A patent/EA201300410A1/ru unknown
- 2011-09-26 MX MX2013002820A patent/MX2013002820A/es not_active Application Discontinuation
- 2011-09-26 CN CN2011800467422A patent/CN103124905A/zh active Pending
- 2011-09-26 WO PCT/EP2011/066636 patent/WO2012041796A1/en not_active Ceased
- 2011-09-26 PH PH1/2013/500560A patent/PH12013500560A1/en unknown
- 2011-09-26 BR BR112013007405A patent/BR112013007405A2/pt not_active IP Right Cessation
- 2011-09-26 CA CA2807250A patent/CA2807250A1/en not_active Abandoned
- 2011-09-26 JP JP2013529666A patent/JP2013540108A/ja active Pending
- 2011-09-26 KR KR1020137007786A patent/KR20130097196A/ko not_active Withdrawn
-
2013
- 2013-03-01 CL CL2013000595A patent/CL2013000595A1/es unknown
-
2014
- 2014-03-21 US US14/221,370 patent/US9274120B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012041796A1 (en) | 2012-04-05 |
| PH12013500560A1 (en) | 2017-08-09 |
| JP2013540108A (ja) | 2013-10-31 |
| US20140205592A1 (en) | 2014-07-24 |
| EP2622352A1 (en) | 2013-08-07 |
| MX2013002820A (es) | 2013-04-05 |
| AU2011310692A1 (en) | 2013-01-31 |
| CN103124905A (zh) | 2013-05-29 |
| US20120244141A1 (en) | 2012-09-27 |
| EA201300410A1 (ru) | 2014-01-30 |
| KR20130097196A (ko) | 2013-09-02 |
| BR112013007405A2 (pt) | 2016-07-12 |
| CA2807250A1 (en) | 2012-04-05 |
| US9274120B2 (en) | 2016-03-01 |
| EP2622352B1 (en) | 2017-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018011832A (es) | Metodos y composiciones para uso en diagnostico de pacientes con cancer. | |
| CL2012003187A1 (es) | Proteinas de union a il-1 beta humana y ala il-1 alfa humana; conjugado de dicha proteina de unión; composicion para la liberacion de una proteina de unión; composicion farmaceutica. | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| CR20160355A (es) | Anticuerpos neutralizantes de atomegalovirus humanos y uso de los mismos | |
| PT2426148E (pt) | Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue | |
| MX2012004868A (es) | Proteinas de enlace al antigeno il-23 humanas. | |
| BRPI1012993A2 (pt) | "uso de um anticorpo anti-tau ps422 para o tratamento de doenças do cérebro" | |
| CR20110470A (es) | Proteínas de union a il-17 | |
| IT1406051B1 (it) | Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo. | |
| AR081696A1 (es) | Anticuerpo para el diagnostico y/o pronostico de cancer | |
| SV2011003939A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| AR077901A1 (es) | Anticuerpo anti- c-met y su uso para la deteccion y diagnostico del cancer | |
| CL2011000230A1 (es) | Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado. | |
| BR112013024574A2 (pt) | polipeptídeo, uso, método de tratamento de indivíduos portadores de doenças e método de tratamento de indivíduos que possuem doenças com um polipeptídeo | |
| EA201300239A1 (ru) | Антитела к fap и способы их применения | |
| TR201902439T4 (tr) | Fukoz analogları kullanarak in vivo protein fukosilasyonunun inhibisyon yöntemleri . | |
| CL2012000768A1 (es) | Compuestos derivados de acido l-glutamico y l-glutamina marcados con [18f]; procedimiento de preparacion; y su uso para el diagnostico de enfermedades tumorales. | |
| WO2012112911A3 (en) | Devices and methods for optical pathology | |
| BRPI1014595A2 (pt) | procedimento de obtenção de novos derivados naftaleno para o diagnóstico in vivo de doença de alzheimer | |
| WO2008109709A3 (en) | Fluorescent phantom device for light imaging systems | |
| AR088244A1 (es) | oxMIF COMO MARCADOR DE DIAGNOSTICO | |
| CR10842A (es) | Derivados de acetileno y su uso para la union a placas amiloides y su diagnostico por imagenes | |
| SG10201804772UA (en) | Method of imaging living tissue | |
| HRP20170238T1 (hr) | Postupak za pripremu vodenih otopina hiperpolariziranih molekula | |
| BR112012010372A2 (pt) | adaptador cirúrgico para conectar um instrumento médico a um endoscópio, adaptador de conector removível seletivamente para uso na conexão de um dispositivo médico para um endoscópio, acoplamento afunilado configurado para direcionar uma porção de um instrumento médico em um sistema de endoscopia e sistema configurado para desempenhar um procedimento cirúrgico. |